GLP-1 drugs, a class of medications used primarily for type 2 diabetes and obesity, may be associated with a reduced risk of developing certain cancers, according to emerging research. Experts interviewed by Everyday Health caution that the findings are preliminary and that people should not take these drugs solely for cancer prevention at this time.

Key Takeaways

  • Several observational studies have found lower rates of some cancers among people taking GLP-1 drugs.
  • The potential link appears strongest for obesity-related cancers such as colorectal, breast, and liver cancer.
  • Experts stress that the research is not yet conclusive and that the drugs have known side effects.
  • Clinical trials specifically designed to test cancer prevention are still needed.

What the Evidence Shows

A handful of large population studies have reported that patients prescribed GLP-1 receptor agonists, such as semaglutide (found in Ozempic and Wegovy) and liraglutide (Victoza), had lower rates of several malignancies compared to those taking other diabetes medications or no treatment. For example, a 2023 study published in JAMA Network Open found a reduced risk of colorectal cancer in people with diabetes who used GLP-1 drugs. Another analysis from 2024 suggested lower risks for liver and gallbladder cancers.

These findings are plausible because obesity is a well established risk factor for at least 13 types of cancer. GLP-1 drugs help people lose significant weight and improve metabolic health, which may in turn lower cancer risk. However, the current data come from observational studies, not randomized controlled trials. That means the studies can show an association but cannot prove that the drugs themselves cause the lower cancer rates.

How Might GLP-1 Drugs Reduce Cancer Risk?

Scientists propose several mechanisms beyond weight loss. GLP-1 drugs reduce inflammation and improve insulin sensitivity, both of which are linked to cancer development. Chronic inflammation and high insulin levels can promote cell growth and tumor formation. By lowering these factors, GLP-1 medications may create an environment less favorable to cancer.

Additionally, the drugs slow gastric emptying and affect appetite regulation, leading to sustained calorie reduction. Caloric restriction itself has been shown in animal studies to suppress tumor growth. Some researchers also believe that GLP-1 receptors are present on certain cancer cells, and activating them might directly inhibit cell proliferation.

What Experts Say

Dr. Francesco Rubino, a bariatric surgeon and researcher, told Everyday Health that while the early signals are promising, it is too soon to recommend GLP-1 drugs for cancer prevention. He noted that the studies often compare users of GLP-1 drugs to users of other diabetes treatments, and the differences could be due to other factors, such as better overall health monitoring in patients on newer therapies.

Dr. Jennifer Caudle, a family physician and health educator, echoed that caution. She pointed out that the drugs can cause gastrointestinal side effects and are expensive. She advises patients to focus on lifestyle changes such as a healthy diet, exercise, and maintaining a normal body weight, which have strong evidence for reducing cancer risk.

Limitations and Caveats

The observational nature of the studies means residual confounding is possible. People who are prescribed GLP-1 drugs may be more health conscious or have better access to medical care, which could partly explain their lower cancer rates. Moreover, the follow up periods in most studies are relatively short, often less than five years. Since many cancers take years or decades to develop, longer term studies are necessary.

Another limitation is that few studies have examined diverse populations. The majority of participants have been middle aged white individuals with diabetes. It is unclear whether the potential protective effect extends to people without diabetes or to different ethnic groups. Randomized clinical trials specifically designed to test cancer prevention endpoints are needed to confirm the findings.

Frequently Asked Questions

Are GLP-1 drugs approved for cancer prevention?

No. GLP-1 drugs are currently approved only for type 2 diabetes, chronic weight management, and reducing cardiovascular risk in certain patients. Their use for cancer prevention is an off label purpose that has not been evaluated or approved by the FDA.

Which cancers might be affected by GLP-1 drugs?

Observational studies have reported potential reductions in colorectal, liver, gallbladder, pancreatic, and endometrial cancers. All of these cancers are known to be linked to obesity. More research is needed to determine if other cancer types are also affected.

Should I take a GLP-1 drug to reduce my cancer risk?

Experts recommend against taking GLP-1 drugs solely for cancer prevention at this time. The evidence is not strong enough to justify the cost and potential side effects. Anyone interested in these medications should discuss with their doctor the risks and benefits based on their personal health situation.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.